- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02458391
Complete Decongestive Therapy in Breast Cancer-Related Lymphedema
Therapeutic Quantity of Complete Decongestive Therapy in Breast Cancer-Related Lymphedema: A Double Blinded Randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Complete Decongestive Therapy (CDT) is the "gold standard" in lymphedema care and has been found to be efficacious in numerous studies. These studies have varying treatment protocols of intensive phase I CDT with dosing ranging from 2x/wk for a mean of 7.5 wks to 6x/wk until a plateau in arm volumes were achieved. This variability in research does not lend itself to recommendations of evidence-based protocol use of CDT in an outpatient setting.
Although CDT is backed by efficacy studies, the daily dosing given to patients is based on anecdotal rather than evidence-based practice. Because the traditional protocol was developed from "longstanding experience," research is necessary to determine the best dosing of the intensive phase of CDT. The purpose of this study is to investigate what level of dosing in the intensive CDT phase promotes best volume reduction and increased upper extremity function in the breast cancer-related lymphedema patient population. This particular study will answer: What dosing produces best volumetric reduction and upper extremity function in the intensive phase of complete decongestive therapy for outpatients with breast cancer-related lymphedema 2x/wk for 4wks or 4x/wk for 4 wks?
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have active unilateral breast cancer-related lymphedema
- Medically stable
- Have not participated in lymphedema therapy the past 3 months
- An affected limb volume measurement of >10% excess volume
Ages 18-95 years old
- Patients undergoing any medical treatment for their breast cancer diagnosis will be included in this study.
- Patients with any stage breast cancer will be included in this study.
- Patients with a prior diagnosis of breast cancer, other cancer will be included in this study. There is no minimum time requirement that has prolapsed between their diagnosis and this study.
All subjects must have given signed, informed consent prior to registration on study.
Exclusion Criteria:
- Prophylactic treatment indicated
- A presence of upper extremity wounds present
- Active signs of infection or deep vein thrombosis (DVT)
- Bilateral lymphedema present
- Evidence of contraindications to CDT: uncontrolled hypertension, heart disease including congestive heart failure, and renal insufficiency
- Severe lymphedema present as defined by > 30% increase in limb volume
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment 2x/wk
Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
|
Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
|
Experimental: Treatment 4x/wk
Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
|
Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in impairments in function, activity limitations, and participation restrictions
Time Frame: At first treatment appointment (roughly week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
A questionnaire looking at impairments in function, activity limitations, and participation restrictions consists of 29 questions divided into five domains: physical function, mental function, household activities, mobility activities, and life and social activities.
|
At first treatment appointment (roughly week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
Changes from baseline in symptoms associated with lymphedema
Time Frame: At first treatment appointment (week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
This outcome measure will assess the presence of symptoms associated with lymphedema.
|
At first treatment appointment (week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in lymphedema volume
Time Frame: At first treatment appointment (week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
Circumferential measurements by tape measure calculated into volume percentage
|
At first treatment appointment (week 1), after 4 weeks of treatment, at discharge (roughly after 8 weeks), and at a 4 week follow-up session after discharge (up to 12 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Rundquist, PhD, PT, University of Indianapolis
Publications and helpful links
General Publications
- Fu, M.R., Hu, S. Cleland, C.M. Kang, Y. (June, 29, 2012). Measuring lymphedema symptom burdens: A psychometric study. The Multinational Association of Supportive Care in Cancer's annual meeting (MASCC/ISOO): 2012 International Symposium on Supportive Care in Cancer in New York City on June 28-30, 2012.
- Mayrovitz HN, Macdonald J, Davey S, Olson K, Washington E. Measurement decisions for clinical assessment of limb volume changes in patients with bilateral and unilateral limb edema. Phys Ther. 2007 Oct;87(10):1362-8. doi: 10.2522/ptj.20060382. Epub 2007 Aug 7.
- Taylor R, Jayasinghe UW, Koelmeyer L, Ung O, Boyages J. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006 Feb;86(2):205-14.
- Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens MR. Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): reliability and validity. Phys Ther. 2011 Jun;91(6):944-57. doi: 10.2522/ptj.20100087. Epub 2011 Apr 14.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UIndianapolis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema of Upper Limb
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
University of OttawaMcGill University; Horizon Health Network; University of New Brunswick; New Brunswick...UnknownLymphedema of Upper Limb | Mastectomy Related Lymphedema | Lymphedema of Lower Extremity
-
ThuasneNot yet recruitingLymphedema of Upper LimbTurkey
-
Maastricht University Medical CenterCompleted
-
Riphah International UniversityRecruitingLymphedema of Upper LimbPakistan
-
Odense University HospitalDanish Cancer SocietyActive, not recruitingPathologic Processes | Neoplasms | Skin Diseases | Lymphatic Diseases | Postoperative Complications | Breast Cancer | Breast Diseases | Lymphedema | Breast Neoplasm | Surgery | Secondary Lymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema Arm | Iatrogenic Lymphedema | A... and other conditionsDenmark
-
Selçuk UniversityRecruiting
-
University of VigoAsociación Gallega de LinfedemaCompletedLymphedema of Upper LimbSpain
-
Cairo UniversityActive, not recruiting
Clinical Trials on Standard of care complete decongestive therapy
-
Cairo UniversityRecruitingFibrosis | Lower Limb Lymphedema | Cellulitis of LegEgypt
-
Our Lady of the Lake Regional Medical CenterUnknown
-
Our Lady of the Lake HospitalCompletedSecondary Lymphedema | Lymphedema of FaceUnited States
-
Norfolk and Norwich University Hospitals NHS Foundation...CompletedBreast Cancer Related LymphoedemaUnited Kingdom
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingLymphedema, Secondary | Lymphedema of Leg | Lymphedema Related FibrosisUnited States
-
Cairo UniversityNot yet recruiting
-
Hospital Universitario Reina Sofia de CordobaCompletedBreast Cancer Lymphedema | Post-Mastectomy Secondary LymphedemaSpain
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
Izmir Bakircay UniversityBezmialem Vakif University; Istanbul Kent UniversityCompletedLymphedema, Breast Cancer | Lymphedema of Upper LimbTurkey
-
M.D. Anderson Cancer CenterWithdrawnHead and Neck Cancer | Lymphedema | Oral Cancer | Oropharyngeal Cancer